Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.55 |
| ▸ | TLR4 | O00206 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4569158 | 0.88 | TLR4 (0.50) | TLR4TLR2SLC2A1SIRT2CETP | |
| SCHEMBL31220919 | 0.88 | TLR4 (0.50) | TLR4TLR2SLC2A1SIRT2CETP | |
| SCHEMBL3972767 | 0.85 | TLR4 (0.48) | TLR4TLR2SLC2A1SIRT2CETP | |
| SCHEMBL3970976 | 0.85 | TLR4 (0.48) | TLR4TLR2SLC2A1SIRT2CETP | |
| SCHEMBL13881548 | 0.85 | TAAR1 (0.51) | TLR4TLR2SLC2A1SIRT2PARP10 | |
| SCHEMBL31220912 | 0.85 | TAAR1 (0.51) | TLR4TLR2SLC2A1SIRT2PARP10 | |
| SCHEMBL3969096 | 0.84 | TLR4 (0.46) | TLR4TLR2SLC2A1PARP10MAOA | |
| SCHEMBL1002808 | 0.83 | TLR4 (0.46) | TLR4TLR2SLC2A1SIRT2PARP10 | |
| SCHEMBL2202527 | 0.83 | TLR4 (0.46) | TLR4TLR2SLC2A1SIRT2PARP10 | |
| SCHEMBL2204247 | 0.83 | TLR4 (0.46) | TLR4TLR2SLC2A1SIRT2PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | CYP4F2 4298/4885CYP4A11 1129/4885TLR4 595/4885 |
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | CYP4F2 4298/4885CYP4A11 1129/4885TLR4 595/4885 |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | CYP4F2 4298/4885CYP4A11 1129/4885TLR4 595/4885 |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | CYP4F2 4298/4885CYP4A11 1129/4885TLR4 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.